Paclitaxel-induced endothelial dysfunction in living rats is prevented by nicorandil via reduction of oxidative stress

Journal of Pharmacological Sciences

Volumn 119, Issue 4, 2012, Pages 349-358

  Serizawa, Ken Ichi ^a   Yogo, Kenji ^a   Aizawa, Ken ^a   Tashiro, Yoshihito ^a   Takahari, Yoko ^b   Sekine, Kaori ^b   Suzuki, Toshihiko ^b   Ishizuka, Nobuhiko ^a   Ishida, Hideyuki ^b  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b TOKAI UNIVERSITY   (Japan)

Author keywords

Endothelial dysfunction; Flow mediated dilation; Nicorandil; Paclitaxel; Reactive oxygen species

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; DIAZOXIDE; DICHLORODIHYDROFLUORESCEIN; DIHYDRORHODAMINE 123; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ISOSORBIDE DINITRATE; MESSENGER RNA; NICORANDIL; PACLITAXEL; PROTEIN P47 PHOX; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; TEMPOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW VELOCITY; BLOOD VESSEL FUNCTION; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; FEMORAL ARTERY FLOW; FLOW MEDIATED DILATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CORONARY ARTERY ENDOTHELIAL CELL; MALE; NONHUMAN; OXIDATIVE STRESS; RAT;

EID: 84865425180     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12067FP     Document Type: Article

References (38)

1. Kitta Y, Obata JE, Nakamura T, Hirano M, Kodama Y, Fujioka D, et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol. 2009;53:323-330.
2. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation. 2005;112:3306-3313.
3. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231.
4. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294:1215-1223.
5. Shin DI, Kim PJ, Seung KB, Kim DB, Kim MJ, Chang K, et al. Drug-eluting stent implantation could be associated with longterm coronary endothelial dysfunction. Int Heart J. 2007;48:553-567.
6. Pendyala LK, Li J, Shinke T, Geva S, Yin X, Chen JP, et al. Endothelium-dependent vasomotor dysfunction in pig coronary arteries with Paclitaxel-eluting stents is associated with inflammation and oxidative stress. JACC Cardiovasc Interv. 2009;2:253-262.
7. Wessely R, Blaich B, Belaiba RS, Merl S, Gorlach A, Kastrati A, et al. Comparative characterization of cellular and molecular antirestenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery. Thromb Haemost. 2007;97:1003-1012.
8. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002;359:1269-1275.
9. Horinaka S, Yabe A, Yagi H, Ishimitsu T, Yamazaki T, Suzuki S, et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. Circ J. 2010;74:503-509.
10. Horinaka S. Use of nicorandil in cardiovascular disease and its optimization. Drugs. 2011;71:1105-1119.
11. Sekiya M, Sato M, Funada J, Ohtani T, Akutsu H, Watanabe K. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol. 2005;46:63-67.
12. Ishibashi Y, Takahashi N, Tokumaru A, Karino K, Sugamori T, Sakane T, et al. Effects of long-term nicorandil administration on endothelial function, inflammation, and oxidative stress in patients without coronary artery disease. J Cardiovasc Pharmacol. 2008;51:311-316.
13. ATP channel. Clin Chim Acta. 2006;374:100-105.
14. Jones ID, Fuentes VL, Wrigglesworth D, Mort E, Elliott J. Comparison of flow-mediated vasodilation in femoral and brachial arteries in healthy dogs. Am J Vet Res. 2011;72:1029-1037.
15. Weber LP, Al-Dissi A, Marit JS, German TN, Terletski SD. Role of carbon monoxide in impaired endothelial function mediated by acute second-hand tobacco, incense, and candle smoke exposures. Environ Toxicol Pharmacol. 2011;31:453-459.
16. Serizawa K, Yogo K, Aizawa K, Tashiro Y, Ishizuka N. Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic rats. Cardiovasc Diabetol. 2011;10:105.
17. Kim DW, Kwon JS, Kim YG, Kim MS, Lee GS, Youn TJ, et al. Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model. Circulation. 2004;109:1558-1563.
18. 3-induced thrombus formation through the inhibition of reactive oxygen species production. Circ J. 2009;73:554-561.
19. Wang S, Peng Q, Zhang J, Liu L. Na+/H+ exchanger is required for hyperglycaemia-induced endothelial dysfunction via calcium-dependent calpain. Cardiovasc Res. 2008;80:255-262.
20. Muller G, Morawietz H. NAD(P)H oxidase and endothelial dysfunction. Horm Metab Res. 2009;41:152-158.
21. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation. 2004;109:II27-II33.
22. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 1986;320:454-456.
23. Jang HJ, Hwang S, Cho KY, Kim do K, Chay KO, Kim JK. Taxol induces oxidative neuronal cell death by enhancing the activity of NADPH oxidase in mouse cortical cultures. Neurosci Lett. 2008;443:17-22.
24. Muldowney JA 3rd, Stringham JR, Levy SE, Gleaves LA, Eren M, Piana RN, et al. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Arterioscler Thromb Vasc Biol. 2007;27:400-406.
25. Pires NM, Eefting D, de Vries MR, Quax PH, Jukema JW. Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. Heart. 2007;93:922-927.
26. Pasquier E, Carre M, Pourroy B, Camoin L, Rebai O, Briand C, et al. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther. 2004;3:1301-1310.
27. Tawa M, Yamamizu K, Geddawy A, Shimosato T, Imamura T, Ayajiki K, et al. Impairment by hypoxia or hypoxia/reoxygenation of nitric oxide-mediated relaxation in isolated monkey coronary artery: the role of intracellular superoxide. J Pharmacol Sci. 2011;116:188-196.
28. ATP channel. Eur J Pharmacol. 2008;579:86-92.
29. Ozcan C, Bienengraeber M, Dzeja PP, Terzic A. Potassium channel openers protect cardiac mitochondria by attenuating oxidant stress at reoxygenation. Am J Physiol Heart Circ Physiol. 2002;282:H531-H539.
30. Yamamoto K, Ando J. New molecular mechanisms for cardiovascular disease:blood flow sensing mechanism in vascular endothelial cells. J Pharmacol Sci. 2011;116:323-331.
31. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 2000;20:2032-2037.
32. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003;111:1201-1209.
33. Crabtree MJ, Hale AB, Channon KM. Dihydrofolate reductase protects endothelial nitric oxide synthase from uncoupling in tetrahydrobiopterin deficiency. Free Radic Biol Med. 2011;50:1639-1646.
34. Rojas A, Romay S, Gonzalez D, Herrera B, Delgado R, Otero K. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. Circ Res. 2000;86:E50-E54.
35. Heiss C, Sievers RE, Amabile N, Momma TY, Chen Q, Natarajan S, et al. In vivo measurement of flow-mediated vasodilation in living rats using high-resolution ultrasound. Am J Physiol Heart Circ Physiol. 2008;294:H1086-H1093.
36. Mailloux A, Grenet K, Bruneel A, Beneteau-Burnat B, Vaubourdolle M, Baudin B. Anticancer drugs induce necrosis of human endothelial cells involving both oncosis and apoptosis. Eur J Cell Biol. 2001;80:442-449.
37. ATP channels, and protein kinase C. J Am Coll Cardiol. 2002;40:1523-1530.
38. Ono H, Osanai T, Ishizaka H, Hanada H, Kamada T, Onodera H, et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am Heart J. 2004;148:E15.